|
||
|
The total reimbursement amount for the three bisphosphonates paid by the NHIF in the RBG and RNM (2015–2018). |
|
||||||||
| Part of: Chakuleska L, Simeonova R, Danchev N (2020) Pharmacotherapy costs and medicines reimbursement policies of osteoporosis in the Republic of Bulgaria and Republic of North Macedonia. Pharmacia 67(4): 199-207. https://doi.org/10.3897/pharmacia.67.e55835 |